6533b821fe1ef96bd127c1ea
RESEARCH PRODUCT
The GERMELATOX DeCOG-trial: Attitude of German melanoma patients towards toxicity during adjuvant interferon treatment-Differences between the patient's and the physician's perspective
Christoffer GebhardtAndrea ForschnerBarbara StadeRalf GutzmerClaus GarbeElisabeth LivingstoneKatharina C. KaehlerLucie HeinzerlingTobias WagnerT. KornekPatrick TerheydenChristine BlomeAxel HauschildBerenice M. RudolphLara Valeska MaulMatthias AugustinCarmen LoquaiDirk Schadendorfsubject
OncologyCancer Researchmedicine.medical_specialtybusiness.industrymedicine.medical_treatmentMelanomaPerspective (graphical)medicine.diseaselanguage.human_languageGermanOncologyInterferonInternal medicineToxicityImmunologymedicinelanguagebusinessneoplasmsAdjuvantmedicine.drugdescription
e20099 Background: Although trials of adjuvant interferon alfa-2b (IFNa-2b) in high-risk melanoma patients suggest improvement in disease-free survival (DFS), metaanalyses showed only a marginal ov...
year | journal | country | edition | language |
---|---|---|---|---|
2015-05-20 |